Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data
Date:4/3/2008

SYDNEY, Australia, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product rhDNase(1). The improvement in lung function after three months on Bronchitol reflects that seen in a previous study following two weeks of treatment.

The study was an independent investigator initiated study conducted in the United Kingdom in 20 children with a mean age of 13 years. Those children enrolled in the trial completed three months treatment with each of three different therapies - Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial measured changes in lung function, airway inflammation, infections, and quality of life.

At the end of the treatment period, lung function as determined by measuring FEV1 (the amount of air that can be forcibly exhaled in 1 second) improved by:

-- 7% while the subjects were on Bronchitol

-- 7% while subjects were on rhDNase and

-- 2% while subjects were on both agents together.

The study had insufficient numbers to reach a definitive statistical conclusion.

People affected by cystic fibrosis typically experience a decline in lung function of 1-2% every year of their life, as measured by FEV1.

Pharmaxis Chief Executive Officer Alan Robertson said: 'While not on the regulatory approval path, this is the first time we have had an opportunity to measure the performance of Bronchitol following 3 months continuous treatment and it bodes well for the pivotal 6 month Phase 3 trial that is currently in progress. Although the two agents worked less well when taken together, the patient numbers are low and a previous study has shown a benefit to using both therapies together.'

Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. rhDNase is designed to improve mucus viscosity. Additional data from this trial will be presented by the independent investigator at a forthcoming scientific congress. A European, Pharmaxis sponsored, regulatory Phase III clinical trial, designed to lead to a marketing application for Bronchitol in adults and children with cystic fibrosis, is currently enrolling subjects.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au.

1: rhDNase is marketed as Pulmozyme, which is a trade mark of Genentech

Inc.

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT: Alan Robertson - Chief Executive Officer

Ph: +61 2 9454 7200 or email alan.robertson@pharmaxis.com.au

Released through:

Australia: Virginia Nicholls, phone +61 417 610 824 or email virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group, phone +1 646 378 2915 or email blewis@troutgroup.com

About the Trial

The following information is provided in accord with the ASX and AusBiotech Code of Best Practice for Reporting by Biotechnology, Medical Device and other Life Sciences Companies.

Name of Trial DPM - CF-203 (A phase II study with

Bronchitol)

Blinding Status Open label

Placebo Controlled No

Treatment Method

Route Inhalation

Frequency Twice per day

Dose levels 400 mg

Number of Subjects 20 evaluable

Subject Selection Criteria Subjects with a known diagnosis of cystic

fibrosis, FEV1 < 70% of predicted, of either

gender, aged between 8 and 19 years of age and

currently receiving rhDNase or eligible to

receive rhDNase.

Primary End Points To compare and contrast the effect on FEV1 of:

1: Bronchitol to rhDNase

2: Bronchitol + rhDNase to rhDNase

Secondary End Points To assess whether:

1: the effects of Bronchitol are additive to

rhDNase

2: Bronchitol reduces the bacterial load in

the lung

3: the effects of Bronchitol are beneficial

to quality of life

Trial Location United Kingdom

Commercial partners Pharmaxis Ltd

Sponsor Investigator initiated, Pharmaxis supported

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 2017 , ... Litmus Health , a clinical data ... board. The board comprises leaders spanning business, technology, academia, and pharmaceutical research. The ... Engineering, to Chief Technology Officer. Crooks will lead strategy and development of the ...
(Date:7/20/2017)... July 20, 2017   KCNQ2 Cure Alliance ... evaluations company, today announced that they have completed ... genetic mutation implicated in KCNQ2 epileptic encephalopathy. They ... a second case involving an additional KCNQ2 genetic ... Alliance and Pairnomix entered into a collaboration to ...
(Date:7/18/2017)... Diego, CA (PRWEB) , ... July 18, 2017 ... ... graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of a ... The new biosensor chip enables researchers to study the kinetics of polyhistidine-tagged (His-tagged) ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... from the United States Patent and Trademark Office for its Patent Applications 14/858,857 ... Trademark Office’s allowances of these patent applications further expand the protection of G-CON’s ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):